

**Blue Cross and Blue Shield of Vermont and The Vermont Health Plan**  
**Prior Approval Form**  
**Lovenox® (Enoxaparin)**  
 BCBSVT and TVHP Fax # (888)-255-1006

**PLEASE COMPLETE THE FOLLOWING SECTIONS:**

Date of Request \_\_\_\_\_ Patient Name: \_\_\_\_\_  
 Member ID#: \_\_\_\_\_ Date of Birth: \_\_\_\_\_  
 Provider Name: \_\_\_\_\_ Provider Phone: \_\_\_\_\_  
 Provider Fax: \_\_\_\_\_ PCP Name: \_\_\_\_\_  
 Patient Weight: \_\_\_\_\_

**INDICATIONS FOR USE:** *(if this is a renewal proceed to question 8)*

	<u>YES</u>	<u>NO</u>
1. Patient has undergone abdominal, hip, and/or knee replacement surgery <b>and</b> is at risk of thromboembolic complications: DVT and PE.	<input type="checkbox"/>	<input type="checkbox"/>
2. Patient's mobility is restricted during an acute illness (defined as a walking distance of <10 meters for ≤3 days).	<input type="checkbox"/>	<input type="checkbox"/>
3. Patient has unstable angina or non Q-wave myocardial infarction and is at risk for thromboembolic complications <b>only</b> when concurrently administered with aspirin.	<input type="checkbox"/>	<input type="checkbox"/>
4. Treatment of acute DVT with or without PE <b>only</b> when administered in conjunction with warfarin. [At least 5 days of overlap is necessary until the INR is therapeutic (2-3). Once INR is therapeutic an additional 2 days of overlap is recommended].	<input type="checkbox"/>	<input type="checkbox"/>
5. Patient is hemodynamically stable.	<input type="checkbox"/>	<input type="checkbox"/>
6. Patient's liver function tests are within normal limits (ALT 7-53 IU/L and AST 11-47 IU/L)	<input type="checkbox"/>	<input type="checkbox"/>
7. Patient is ≥ 18 years of age.	<input type="checkbox"/>	<input type="checkbox"/>
8. <b>If this is a renewal:</b> Has the patient demonstrated appropriate anticoagulation?	<input type="checkbox"/>	<input type="checkbox"/>

**REASONS FOR BENEFIT DENIAL:**

	<u>YES</u>	<u>NO</u>
1. Patient is at risk of hemorrhage.	<input type="checkbox"/>	<input type="checkbox"/>
2. Has patient recently undergone neuroaxial anesthesia or spinal puncture ( <b>Black Box Warning</b> ).	<input type="checkbox"/>	<input type="checkbox"/>
3. Patient is thrombocytopenic (platelet count ≤100,000/mm <sup>3</sup> ).	<input type="checkbox"/>	<input type="checkbox"/>
4. Patient has a hypersensitivity to enoxaparin sodium, heparin, or pork products.	<input type="checkbox"/>	<input type="checkbox"/>
5. Individual is considered a low risk general/minor surgery patient <40 years of age with no additional risk factors.	<input type="checkbox"/>	<input type="checkbox"/>

**If patient meets criteria:** • Initial approval: 30 days and a quantity limit: 30 inj/30 days • Renewal approval period: 1 month

Dose: \_\_\_\_\_ Frequency: \_\_\_\_\_ Duration of Therapy: \_\_\_\_\_

PRESCRIBER SIGNATURE \_\_\_\_\_ DATE \_\_\_\_\_

**By signing above, the prescriber confirms all information provided is accurate and verifiable via member records.**